World Pathology: Gastric Cancer

• Publication date: April 2011

The report is an essential source of information and analysis on the global gastric cancer therapeutics industry . The report provides comprehensive data on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the major industry developments shaping and driving the global gastric cancer therapeutics industry . It analyses the treatment usage patterns in the global gastric cancer therapeutics industry . The report also...

The report is an essential source of information and analysis on the global gastric cancer therapeutics industry . The report provides comprehensive data on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the major industry developments shaping and driving the global gastric cancer therapeutics industry . It analyses the treatment usage patterns in the global gastric cancer therapeutics industry . The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing industry leaders. The report provides valuable insights into the new product development within the global gastric cancer segment . It quantifies the unmet need in the global gastric cancer therapeutics industry as well as in the individual industry s such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

Scope of the Research

The

Scope of the Research of the report includes:
- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global gastric cancer therapeutics industry revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, projection for 11 years to 2020.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key market drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales projections .
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales projection .
- Analysis of unmet need in the industry and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.
- Clinical trials mapping of trials for gastric cancer in different regions.
- An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, industry ing rights, and launch analysis and drug sales forcasts to 2020.
- Analysis of the current and future industry competition in the global Gastric Cancer therapeutics industry . Firms profiles including business description, financial overview and SWOT analysis. Key industry players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Firms, Otsuka and Merck KGaA.
- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics industry . Merger and Acquisition analysis which includes Merger and Acquisition deals by size and geography.
- Strategic assessment of the industry through industry impact analysis, future industry scenario and industry player analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics industry .

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior industry quantification analysis by
- Understanding the trends shaping and driving the global gastric cancer therapeutics industry .
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing industry sizing, projections and quantified growth opportunities in the global gastric cancer therapeutics industry till 2020.
- Quantifying patient population in the global gastric cancer industry to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and industry ing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently industry ed products
- Identifying industry entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in industry by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the global gastric cancer therapeutics industry from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the global gastric cancer therapeutics industry landscape? Identify, understand and capitalize

Global Therapy Industry

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 7
I. 2 List of Charts 10

II Introduction 14
II. 1 Disease Data 14
II. 1.1 TNM (Tumor, Nodes, Metastasis) Staging System 14
II. 2 Epidemiology 16
II. 3 Etiology 16
II. 4 Symptoms 17
II. 4.1 Initial Symptoms 17
II. 4.2 Symptoms Observed in Later Stages 17
II. 5 Diagnosis 18
II. 5.1 Fecal Occult Blood Test (FOBT) 18
II. 5.2 X-ray of Upper Gastrointestinal Tract (GI Series) 19
II. 5.3 Endoscopy (Gastroscopy) 19
II. 5.4 Computed Tomography (CT) 20
II. 5.5 Biopsy 20
II. 6 Pathology 20
II. 6.1 Grading 21
II. 7 Prognosis 22
II. 8 Treatment 22
II. 8.1 Gastric Cancer Treatment Options 23
II. 9 Treatment Guidelines 27
II. 10 GlobalData Report Guidance 28

III March ket Characterization 29
III. 1 World 29
III. 1.1 March ket Size 29
III. 1.2 Drivers and Restraints 37
III. 1.3 Forecasted data s 39
III. 1.4 Drug Sales 46
III. 2 The US 50
III. 2.1 March ket Size 50
III. 2.2 Drivers and Restraints 56
III. 2.3 Forecasted data s 59
III. 2.4 Drug Sales 65
III. 2.5 Pricing and Reimbursements 68
III. 3 The UK 69
III. 3.1 March ket Size 69
III. 3.2 Drivers and Restraints 75
III. 3.3 Impact on the March ket 77
III. 3.4 Forecasted data s 78
III. 3.5 Drug Sales 84
III. 3.6 Pricing and Reimbursements 87
III. 4 Germany 88
III. 4.1 March ket Size 88
III. 4.2 Drivers and Restraints 94
III. 4.3 Impact on the March ket 96
III. 4.4 Forecasted data s 97
III. 4.5 Drug Sales 103
III. 4.6 Pricing and Reimbursements 106
III. 5 France 107
III. 5.1 March ket Size 107
III. 5.2 Drivers and Restraints 113
III. 5.3 Impact on the March ket 114
III. 5.4 Forecasted data s 115
III. 5.5 Drug Sales 121
III. 5.6 Pricing and Reimbursements 124
III. 6 Italy 125
III. 6.1 March ket Size 125
III. 6.2 Drivers and Restraints 131
III. 6.3 Impact on the March ket 133
III. 6.4 Forecasted data s 134
III. 6.5 Drug Sales 140
III. 6.6 Pricing and Reimbursements 143
III. 7 Spain 144
III. 7.1 March ket Size 144
III. 7.2 Drivers and Restraints 150
III. 7.3 Impact on the March ket 152
III. 7.4 Forecasted data s 153
III. 7.5 Drug Sales 159
III. 7.6 Pricing and Reimbursements 162
III. 8 Japan 163
III. 8.1 March ket Size 163
III. 8.2 Drivers and Restraints 168
III. 8.3 Impact on the March ket 169
III. 8.4 Forecasted data s 170
III. 8.5 Future Impact 175
III. 8.6 Drug Sales 176
III. 8.7 Pricing and Reimbursements 179
III. 9 Brazil 180
III. 9.1 March ket Size 180
III. 9.2 Drivers and Restraints 185
III. 9.3 Impact on the March ket 186
III. 9.4 Forecasted data s 187
III. 9.5 Future Impact 193
III. 10 Russia 194
III. 10.1 March ket Size 194
III. 10.2 Drivers and Restraints 199
III. 10.3 Impact on the March ket 200
III. 10.4 Forecasted data s 201
III. 10.5 Future Impact 206
III. 11 India 207
III. 11.1 March ket Size (from 2002 to 2010 ) 207
III. 11.2 Drivers and Restraints 212
III. 11.3 Impact on the March ket 213
III. 11.4 Forecasted data s (2010-2020) 214
III. 11.5 Future Impact 219
III. 12 China 220
III. 12.1 March ket Size (from 2002 to 2010 ) 220
III. 12.2 Drivers and Restraints 225
III. 12.3 Impact on the March ket 226
III. 12.4 Impact on the March ket 226
III. 12.5 Forecasted data s (2010-2020) 227
III. 12.6 Future Impact 232
III. 13 Key Takeaway 232

IV Gastric Cancer March ket: Competitive Assessment 233
IV. 1 Strategic Competitor Assessment 233
IV. 1.1 Overview 233
IV. 1.2 Benchmarking 234
IV. 1.3 Current Competitor Assessment 236
IV. 2 Launch Analysis and Sales Forecasted data s 238
IV. 3 Product Profiles of Major March keted Drugs in the Gastric Cancer March ket 239
IV. 3.1 Herceptin (trastuzumab) 239
IV. 3.2 Taxotere (docetaxel) 242
IV. 3.3 Teysuno 243
IV. 3.4 Xeloda 245
IV. 4 Key Takeaway 246

V Gastric Cancer March ket: Pipeline Assessment 247
V. 1 Overview 247
V. 2 Pipeline Analysis by Phase of Development 247
V. 3 Pipeline by Mechanism of Action 248
V. 4 Strategic Pipeline Assessment 249
V. 4.1 Technology Trends Analytic Framework 249
V. 5 Gastric Cancer – Promising Drugs Under Clinical Development 251
V. 6 Partners in Development 252
V. 6.1 Licensing Agreements 252
V. 6.2 Research and Development Partnership Agreements 253
V. 6.3 Technology and Diagnostic Agreements 255
V. 7 Molecule Profile for Promising Drugs Under Clinical Development 256
V. 7.1 Tykerb (Lapatinib) 256
V. 7.2 Afinitor (Everolimus) 257
V. 7.3 IMC-1121B (ramucirumab) 257
V. 7.4 Cetuximab plus capecitabine and cisplatin 258
V. 7.5 Apatinib (YN968DI) 258
V. 8 Key Takeaway 259

VI Clinical Trials Mapping 260
VI. 1 Clinical Trials 260
VI. 1.1 Clinical Trials by Status 260
VI. 1.2 Clinical Trials by Country 261
VI. 1.3 Clinical Trials by Phase 262
VI. 1.4 Clinical Trials by Sponsor Type 263
VI. 1.5 Clinical Trials – Leading Sponsors 264
VI. 1.6 Clinical Trials – Leading Firms Sponsors by Phase 265
VI. 2 Patient Recruitment 266

VII Opportunity and Unmet Need 267
VII. 1 Unmet Need 267
VII. 2 Opportunity for Target Products 269
VII. 3 Key Takeaway 270

VIII Strategic Assessment 271
VIII. 1 Key Events Impacting the Future March ket 271
VIII. 2 March ket Impact Analysis 272
VIII. 3 Future March ket Scenario 272

IX Gastric Cancer March ket: Future Players 274
IX. 1 Introduction 274
IX. 2 November artis AG 275
IX. 2.1 Business Overview 275
IX. 2.2 Financial Overview 276
IX. 2.3 Gastric Cancer Pipeline 276
IX. 2.4 SWOT 277
IX. 3 GlaxoSmithKline 283
IX. 3.1 Business Overview 283
IX. 3.2 Financial Overview 284
IX. 3.3 Gastric Cancer Pipeline 284
IX. 3.4 SWOT 285
IX. 4 Hoffmann-La Roche Ltd. 291
IX. 4.1 Business Overview 291
IX. 4.2 Financial Performance 293
IX. 4.3 Gastric Cancer Pipeline 293
IX. 4.4 SWOT 294
IX. 5 Eli Lilly and Firms 298
IX. 5.1 Business Overview 298
IX. 5.2 Financial Overview 300
IX. 5.3 Gastric Cancer Pipeline 300
IX. 5.4 SWOT 301
IX. 6 Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd. 306
IX. 6.1 Business Overview 306
IX. 6.2 Gastric Cancer Products 306
IX. 7 Merck KGaA 307
IX. 7.1 Business Overview 307
IX. 7.2 Financial Overview 307
IX. 7.3 Gastric Cancer Pipeline 307
IX. 7.4 SWOT 308

X Gastric Cancer March ket: Players in the Gastric Cancer March ket 313
X. 1 Sanofi-aventis 313
X. 1.1 Business Overview 313
X. 1.2 Financial Overview 315
X. 1.3 SWOT 315
X. 1.4 Oncology Focus 320

XI M&A Analysis 321
XI. 1 Key Highlights 321
XI. 2 Key Deals’ Analysis 323
XI. 2.1 CrystalGenomics Completes Merger with BexPharm 323
XI. 2.2 Astellas Pharma Takes Over OSI Pharmaceuticals 323
XI. 2.3 Eli Lilly Takes Over ImClone 323
XI. 2.4 Roche Takes Over Additional 9.8% Stake in Chugai Pharmaceuticals 324

XII Expert Opinion 325
XII. 1 The US 325
XII. 2 Germany 326
XII. 3 Italy 326
XII. 4 Spain 327
XII. 5 Japan 328

XIII Appendix 329
XIII. 1 March ket Definitions 329
XIII. 2 Abbreviations 329
XIII. 3 Research Methodology 330
XIII. 3.1 Coverage 330
XIII. 3.2 Secondary Research 331
XIII. 3.3 Forecasted data ing 331
XIII. 3.4 Primary Research 334
XIII. 3.5 Expert Panel validation 334
XIII. 3.6 Contact Us 334
XIII. 3.7 Disclaimer 334
XIII. 3.8 Sources 335

1.1 List of Data tables
Data table 1: Gastric Cancer Therapeutics March ket, Global, Staging of Gastric Cancer, 2010 15
Data table 2: Gastric Cancer Therapeutics March ket, Global, Risk Factors, 2010 16
Data table 3: Gastric Cancer, Global, Results of GI Series X-ray, 2010 19
Data table 4: Gastric Cancer, Global, WHO Classification of Gastric Carcinomas, 2010 21
Data table 5: Gastric Cancer, Global, Five Year Relative Survival by Stage, 2010 22
Data table 6: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011 25
Data table 7: Gastric Cancer, Global, Sales Value (USD Million), from 2002 to 2010 29
Data table 8: Gastric Cancer Therapeutics March ket, Global, Sales Value (USD Million) by Country, from 2002 to 2010 31
Data table 9: Gastric Cancer Therapeutics March ket, Global, Annual Cost of Therapy ($), from 2002 to 2010 33
Data table 10: Gastric Cancer Therapeutics March ket, Global, Patient Volume (’000s), from 2002 to 2010 34
Data table 11: Gastric Cancer Therapeutics March ket, Global, Treatment Usage Patterns (’000s), from 2002 to 2010 35
Data table 12: Gastric Cancer Therapeutics March ket, Global, Sales Value (USD Million), from 2010 to 2020 39
Data table 13: Gastric Cancer Therapeutics March ket, Global, Sales Value (USD Million) by Country, from 2010 to 2020 40
Data table 14: Gastric Cancer Therapeutics March ket, Global, Annual Cost of Therapy ($), from 2010 to 2020 41
Data table 15: Gastric Cancer Therapeutics March ket, Global, Patient Volume (’000s), from 2010 to 2020 42
Data table 16: Gastric Cancer Therapeutics March ket, Global, Treatment Usage Patterns (’000s), from 2010 to 2020 43
Data table 17: Gastric Cancer Therapeutics March ket, Global, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 47
Data table 18: Gastric Cancer Therapeutics March ket, Global, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 48
Data table 19: Gastric Cancer Therapeutics March ket, the US, Sales Value ($bn), from 2002 to 2010 50
Data table 20: Gastric Cancer Therapeutics March ket, the US, Annual Cost of Therapy ($), from 2002 to 2010 51
Data table 21: Gastric Cancer Therapeutics March ket, the US, Patient Volume (Absolute), from 2002 to 2010 52
Data table 22: Gastric Cancer Therapeutics March ket, the US, Treatment Usage Patterns (’000s), from 2002 to 2010 54
Data table 23: Gastric Cancer Therapeutics March ket, the US, Sales Value (USD Million), from 2010 to 2020 59
Data table 24: Gastric Cancer Therapeutics March ket, the US, Annual Cost of Therapy ($), from 2010 to 2020 60
Data table 25: Gastric Cancer Therapeutics March ket, the US, Patient Volume (Absolute), from 2010 to 2020 61
Data table 26: Gastric Cancer Therapeutics March ket, the US, Treatment Usage Patterns (’000s), from 2010 to 2020 62
Data table 27: Gastric Cancer Therapeutics March ket, the US, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 66
Data table 28: Gastric Cancer Therapeutics March ket, the US, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 67
Data table 29: Gastric Cancer Therapeutics March ket, the UK, Sales Value (USD Million), from 2002 to 2010 69
Data table 30: Gastric Cancer Therapeutics March ket, the UK, Annual Cost of Therapy ($), from 2002 to 2010 71
Data table 31: Gastric Cancer Therapeutics March ket, the UK, Patient Volume (Absolute), from 2002 to 2010 72
Data table 32: Gastric Cancer Therapeutics March ket, the UK, Treatment Usage Patterns (’000s), from 2002 to 2010 73
Data table 33: Gastric Cancer Therapeutics March ket, the UK, Sales Value (USD Million), from 2010 to 2020 78
Data table 34: Gastric Cancer Therapeutics March ket, the UK, Annual Cost of Therapy ($), from 2010 to 2020 79
Data table 35: Gastric Cancer Therapeutics March ket, the UK, Patient Volume (Absolute), from 2010 to 2020 80
Data table 36: Gastric Cancer Therapeutics March ket, the UK, Treatment Usage Patterns (’000s), from 2010 to 2020 81
Data table 37: Gastric Cancer Therapeutics March ket, the UK, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 85
Data table 38: Gastric Cancer Therapeutics March ket, the UK, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 86
Data table 39: Gastric Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2002 to 2010 88
Data table 40: Gastric Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2002 to 2010 90
Data table 41: Gastric Cancer Therapeutics March ket, Germany, Patient Volume (Absolute), from 2002 to 2010 91
Data table 42: Gastric Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2002 to 2010 92
Data table 43: Gastric Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2010 to 2020 97
Data table 44: Gastric Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2010 to 2020 98
Data table 45: Gastric Cancer Therapeutics March ket, Germany, Patient Volume (Absolute), from 2010 to 2020 99
Data table 46: Gastric Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2010 to 2020 100
Data table 47: Gastric Cancer Therapeutics March ket, Germany, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 104
Data table 48: Gastric Cancer Therapeutics March ket, Germany, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 105
Data table 49: Gastric Cancer Therapeutics March ket, France, Sales Value (USD Million), from 2002 to 2010 107
Data table 50: Gastric Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), from 2002 to 2010 109
Data table 51: Gastric Cancer Therapeutics March ket, France, Patient Volume (Absolute), from 2002 to 2010 110
Data table 52: Gastric Cancer Therapeutics March ket, France, Treatment Usage Patterns (’000s), from 2002 to 2010 111
Data table 53: Gastric Cancer Therapeutics March ket, France, Sales Value (USD Million), from 2010 to 2020 115
Data table 54: Gastric Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), from 2010 to 2020 116
Data table 55: Gastric Cancer Therapeutics March ket, France, Patient Volume (Absolute), from 2010 to 2020 117
Data table 56: Gastric Cancer Therapeutics March ket, France, Treatment Usage Patterns (’000s), from 2010 to 2020 118
Data table 57: Gastric Cancer Therapeutics March ket, France, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 122
Data table 58: Gastric Cancer Therapeutics March ket, France, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 123
Data table 59: Gastric Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2002 to 2010 125
Data table 60: Gastric Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2002 to 2010 127
Data table 61: Gastric Cancer Therapeutics March ket, Italy, Patient Volume (Absolute), from 2002 to 2010 128
Data table 62: Gastric Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2002 to 2010 129
Data table 63: Gastric Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2010 to 2020 134
Data table 64: Gastric Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2010 to 2020 135
Data table 65: Gastric Cancer Therapeutics March ket, Italy, Patient Volume (Absolute), from 2010 to 2020 136
Data table 66: Gastric Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2010 to 2020 137
Data table 67: Gastric Cancer Therapeutics March ket, Italy, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 141
Data table 68: Gastric Cancer Therapeutics March ket, Italy, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 142
Data table 69: Gastric Cancer Therapeutics March ket, Spain, Sales Value (USD Million), from 2002 to 2010 144
Data table 70: Gastric Cancer Therapeutics March ket, Spain, Annual Cost of Therapy ($), from 2002 to 2010 146
Data table 71: Gastric Cancer Therapeutics March ket, Spain, Patient Volume (Absolute), from 2002 to 2010 147
Data table 72: Gastric Cancer Therapeutics March ket, Spain, Treatment Usage Patterns (’000s), from 2002 to 2010 148
Data table 73: Gastric Cancer Therapeutics March ket, Spain, Sales Value (USD Million), from 2010 to 2020 153
Data table 74: Gastric Cancer Therapeutics March ket, Spain, Annual Cost of Therapy ($), from 2010 to 2020 154
Data table 75: Gastric Cancer Therapeutics March ket, Spain, Patient Volume (Absolute), from 2010 to 2020 155
Data table 76: Gastric Cancer Therapeutics March ket, Spain, Treatment Usage Patterns (’000s), from 2010 to 2020 156
Data table 77: Gastric Cancer Therapeutics March ket, Spain, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 160
Data table 78: Gastric Cancer Therapeutics March ket, Spain, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 161
Data table 79: Gastric Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2002 to 2010 163
Data table 80: Gastric Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2002 to 2010 164
Data table 81: Gastric Cancer Therapeutics March ket, Japan, Patient Volume (Absolute), from 2002 to 2010 165
Data table 82: Gastric Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2002 to 2010 166
Data table 83: Gastric Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2010 to 2020 170
Data table 84: Gastric Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2010 to 2020 171
Data table 85: Gastric Cancer Therapeutics March ket, Japan, Patient Volume (Absolute), from 2010 to 2020 172
Data table 86: Gastric Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2010 to 2020 173
Data table 87: Gastric Cancer Therapeutics March ket, Japan, Gastric Cancer Drug Sales (USD Million), from 2002 to 2010 177
Data table 88: Gastric Cancer Therapeutics March ket, Japan, Gastric Cancer Drug Sales (USD Million), from 2011 to 2020 178
Data table 89: Gastric Cancer Therapeutics March ket, Brazil, Sales Value (USD Million), from 2002 to 2010 180
Data table 90: Gastric Cancer Therapeutics March ket, Brazil, Annual Cost of Therapy ($), from 2002 to 2010 181
Data table 91: Gastric Cancer Therapeutics March ket, Brazil, Patient Volume (Absolute), from 2002 to 2010 182
Data table 92: Gastric Cancer Therapeutics March ket, Brazil, Treatment Usage Patterns (’000s), from 2002 to 2010 183
Data table 93: Gastric Cancer Therapeutics March ket, Brazil, Sales Value (USD Million), from 2010 to 2020 187
Data table 94: Gastric Cancer Therapeutics March ket, Brazil, Annual Cost of Therapy ($), from 2010 to 2020 188
Data table 95: Gastric Cancer, Brazil, Patient Volume (Absolute), from 2010 to 2020 189
Data table 96: Gastric Cancer Therapeutics March ket, Brazil, Treatment Usage Patterns (’000s), from 2010 to 2020 191
Data table 97: Gastric Cancer, Russia, Sales Value (USD Million), from 2002 to 2010 194
Data table 98: Gastric Cancer, Russia, Annual Cost of Therapy ($), from 2002 to 2010 195
Data table 99: Gastric Cancer, Russia, Patient Volume (Absolute), from 2002 to 2010 196
Data table 100: Gastric Cancer, Russia, Treatment Usage Patterns, from 2002 to 2010 197
Data table 101: Gastric Cancer, Russia, Sales Value (USD Million), from 2010 to 2020 201
Data table 102: Gastric Cancer, Russia, Annual Cost of Therapy ($), from 2010 to 2020 202
Data table 103: Gastric Cancer, Russia, Patient Volume (Absolute), from 2010 to 2020 203
Data table 104: Gastric Cancer, Russia, Treatment Usage Patterns, from 2010 to 2020 204
Data table 105: Gastric Cancer, India, Sales Value (USD Million), from 2002 to 2010 207
Data table 106: Gastric Cancer, India, Annual Cost of Therapy ($), from 2002 to 2010 208
Data table 107: Gastric Cancer, India, Patient Volume (Absolute), from 2002 to 2010 209
Data table 108: Gastric Cancer, India, Treatment Usage Patterns, from 2002 to 2010 210
Data table 109: Gastric Cancer, India, Sales Value (USD Million), from 2010 to 2020 214
Data table 110: Gastric Cancer, India, Annual Cost of Therapy ($), from 2010 to 2020 215
Data table 111: Gastric Cancer, India, Patient Volume (Absolute), from 2010 to 2020 216
Data table 112: Gastric Cancer, India, Treatment Usage Patterns, from 2010 to 2020 217
Data table 113: Gastric Cancer, China, Sales Value (USD Million), from 2002 to 2010 220
Data table 114: Gastric Cancer, China, Annual Cost of Therapy ($), from 2002 to 2010 221
Data table 115: Gastric Cancer, China, Patient Volume (Absolute), from 2002 to 2010 222
Data table 116: Gastric Cancer, China, Treatment Usage Patterns, from 2002 to 2010 223
Data table 117: Gastric Cancer, China, Sales Value (USD Million), from 2010 to 2020 227
Data table 118: Gastric Cancer, China, Annual Cost of Therapy ($), from 2010 to 2020 228
Data table 119: Gastric Cancer, China, Patient Volume (Absolute), from 2010 to 2020 229
Data table 120: Gastric Cancer, China, Treatment Usage Patterns, from 2010 to 2020 230
Data table 121: Gastric Cancer, Global, Clinical Endpoints for Benchmarking, 2010 234
Data table 122: Gastric Cancer, Global, Chemotherapy, Safety Company Profile: Approved Treatment, 2010 235
Data table 123: Gastric Cancer, Global, Benchmarking of Major March keted Products, 2010 239
Data table 124: Gastric Cancer – Most Promising Drugs Under Clinical Development, 2010 251
Data table 125: Gastric Cancer, Global, Licensing Agreements, from 2007 to 2010 252
Data table 126:Gastric Cancer, Global, Research and Development Partnership Agreements, from 2009 to 2010 253
Data table 127: Gastric Cancer, Global, Technology and Diagnostic Agreements, from 2009 to 2010 255
Data table 128: Gastric Cancer Therapeutics March ket, Global, Clinical Trials by Status, 2011 260
Data table 129: Gastric Cancer Therapeutics March ket, Global, Clinical Trials by Country, 2011 261
Data table 130: Gastric Cancer Therapeutics March ket, Global, Clinical Trials by Phase, 2011 262
Data table 131: Gastric Cancer Therapeutics March ket, Global, Clinical Trials by Sponsor Type, 2011 263
Data table 132:Gastric Cancer Therapeutics March ket, Global, Clinical Trials, Leading Sponsors, 2011 264
Data table 133:Gastric Cancer Therapeutics March ket, Global, Clinical Trials, Leading Firms Sponsors, 2011 265
Data table 134:Gastric Cancer Therapeutics March ket, Global, Clinical Trials, Average Number of Patients Recruited, 2011 266
Data table 135: November artis AG – Clinical Pipeline for Gastric Cancer, 2010 276
Data table 136: GlaxoSmithKline – Clinical Pipeline for Gastric Cancer, 2011 284
Data table 137: Roche – Clinical Pipeline for Gastric Cancer, 2011 293
Data table 138: Eli Lilly and Firms – Clinical Pipeline for Gastric Cancer, 2011 300
Data table 139: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011 306
Data table 140: Merck KGaA – Clinical Pipeline for Gastric Cancer, 2011 307
Data table 141: Gastric Cancer, Global, Merger and Acquisition Deals, 2010 322

1.2 List of Charts

Chart 1: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011 23
Chart 2: Gastric Cancer Therapeutics March ket, Global, Treatment Guidelines, 2010 27
Chart 3: Gastric Cancer, Global, Sales Value (USD Million), from 2002 to 2010 29
Chart 4: Gastric Cancer Therapeutics March ket, Global, Sales Value (USD Million) by Country, from 2002 to 2010 31
Chart 5: Gastric Cancer Therapeutics March ket, Global, Annual Cost of Therapy ($), from 2002 to 2010 33
Chart 6: Gastric Cancer Therapeutics March ket, Global, Patient Volume (’000s), from 2002 to 2010 34
Chart 7: Gastric Cancer Therapeutics March ket, Global, Treatment Usage Patterns (’000s), from 2002 to 2010 35
Chart 8: Gastric Cancer, Global, March ket Drivers and Restraints, 2009 37
Chart 9: Gastric Cancer Therapeutics March ket, Global, Historical data al Events Impact on the March ket, 2010 38
Chart 10: Gastric Cancer Therapeutics March ket, Global, Sales Value (USD Million), from 2010 to 2020 39
Chart 11: Gastric Cancer Therapeutics March ket, Global, Sales Value (USD Million) by Country, from 2010 to 2020 40
Chart 12: Gastric Cancer Therapeutics March ket, Global, Annual Cost of Therapy ($), from 2010 to 2020 41
Chart 13: Gastric Cancer Therapeutics March ket, Global, Patient Volume (’000s), from 2010 to 2020 42
Chart 14: Gastric Cancer Therapeutics March ket, Global, Treatment Usage Patterns (’000s), from 2010 to 2020 43
Chart 15: Gastric Cancer Therapeutics March ket, Global, Future March ket Drivers and Restraints, from 2010 to 2020 45
Chart 16: Gastric Cancer Therapeutics March ket, Global, Gastric Cancer Drug Sales (USD Million), from 2001 to 2020 46
Chart 17: Gastric Cancer Therapeutics March ket, Global, Breakdown of Drug Sales (%), 2010 49
Chart 18: Gastric Cancer Therapeutics March ket, the US, Sales Value (USD Million), from 2002 to 2010 50
Chart 19: Gastric Cancer Therapeutics March ket, the US, Annual Cost of Therapy ($), from 2002 to 2010 51
Chart 20: Gastric Cancer Therapeutics March ket, the US, Patient Volume (’000s), from 2002 to 2010 52
Chart 21: Gastric Cancer Therapeutics March ket, the US, Treatment Usage Patterns (’000s), from 2002 to 2010 54
Chart 22: Gastric Cancer Therapeutics March ket, the US, March ket Drivers and Restraints, 2009 56
Chart 23: Gastric Cancer Therapeutics March ket, the the US, Historical data al Events Impact on the March ket, 2010 58
Chart 24: Gastric Cancer Therapeutics March ket, the US, Sales Value (USD Million), from 2010 to 2020 59
Chart 25: Gastric Cancer Therapeutics March ket, the US, Annual Cost of Therapy ($), from 2010 to 2020 60
Chart 26: Gastric Cancer Therapeutics March ket, the US, Patient Volume (’000s), from 2010 to 2020 61
Chart 27: Gastric Cancer Therapeutics March ket, the US, Treatment Usage Patterns (’000s), from 2010 to 2020 62
Chart 28: Gastric Cancer Therapeutics March ket, the US, Future March ket Drivers and Restraints, from 2010 to 2020 64
Chart 29: Gastric Cancer Therapeutics March ket, the US, Gastric Cancer Drug Sales (USD Million), from 2001 to 2020 65
Chart 30: Gastric Cancer Therapeutics March ket, the UK, Sales Value (USD Million), from 2002 to 2010 69
Chart 31: Gastric Cancer Therapeutics March ket, the UK, Annual Cost of Therapy ($), from 2002 to 2010 71
Chart 32: Gastric Cancer Therapeutics March ket, the UK, Patient Volume (’000s), from 2002 to 2010 72
Chart 33: Gastric Cancer Therapeutics March ket, the UK, Treatment Usage Patterns (’000s), from 2002 to 2010 73
Chart 34: Gastric Cancer Therapeutics March ket, the UK, March ket Drivers and Restraints, 2009 75
Chart 35: Gastric Cancer Therapeutics March ket, the UK, Historical data al Events Impact on the March ket, 2010 77
Chart 36: Gastric Cancer Therapeutics March ket, the UK, Sales Value (USD Million), from 2010 to 2020 78
Chart 37: Gastric Cancer Therapeutics March ket, the UK, Annual Cost of Therapy ($), from 2010 to 2020 79
Chart 38: Gastric Cancer Therapeutics March ket, the UK, Patient Volume (’000s), from 2010 to 2020 80
Chart 39: Gastric Cancer Therapeutics March ket, the UK, Treatment Usage Patterns (’000s), from 2010 to 2020 81
Chart 40: Gastric Cancer Therapeutics March ket, the UK, Future March ket Drivers and Restraints, from 2010 to 2020 83
Chart 41: Gastric Cancer Therapeutics March ket, the UK, Gastric Cancer Drug Sales (USD Million), from 2002 to 2020 84
Chart 42: Gastric Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2002 to 2010 88
Chart 43: Gastric Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2002 to 2010 90
Chart 44: Gastric Cancer Therapeutics March ket, Germany, Patient Volume (’000s), from 2002 to 2010 91
Chart 45: Gastric Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2002 to 2010 92
Chart 46: Gastric Cancer Therapeutics March ket, Germany, March ket Drivers and Restraints, 2009 94
Chart 47: Gastric Cancer Therapeutics March ket, Germany, Historical data al Events Impact on the March ket, 2010 96
Chart 48: Gastric Cancer Therapeutics March ket, Germany, Sales Value (USD Million), from 2010 to 2020 97
Chart 49: Gastric Cancer Therapeutics March ket, Germany, Annual Cost of Therapy ($), from 2010 to 2020 98
Chart 50: Gastric Cancer Therapeutics March ket, Germany, Patient Volume (’000s), from 2010 to 2020 99
Chart 51: Gastric Cancer Therapeutics March ket, Germany, Treatment Usage Patterns (’000s), from 2010 to 2020 100
Chart 52: Gastric Cancer Therapeutics March ket, Germany, Future March ket Drivers and Restraints, from 2010 to 2020 102
Chart 53: Gastric Cancer Therapeutics March ket, Germany, Gastric Cancer Drug Sales (USD Million), from 2002 to 2020 103
Chart 54: Gastric Cancer Therapeutics March ket, France, Sales Value (USD Million), from 2002 to 2010 107
Chart 55: Gastric Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), from 2002 to 2010 109
Chart 56: Gastric Cancer Therapeutics March ket, France, Patient Volume (’000s), from 2002 to 2010 110
Chart 57: Gastric Cancer Therapeutics March ket, France, Treatment Usage Patterns (’000s), from 2002 to 2010 111
Chart 58: Gastric Cancer, France, March ket Drivers and Restraints, 2009 113
Chart 59: Gastric Cancer, France, Historical data al Events Impact on the March ket, 2010 114
Chart 60: Gastric Cancer Therapeutics March ket, France, Sales Value (USD Million), from 2010 to 2020 115
Chart 61: Gastric Cancer Therapeutics March ket, France, Annual Cost of Therapy ($), from 2010 to 2020 116
Chart 62: Gastric Cancer Therapeutics March ket, France, Patient Volume (’000s), from 2010 to 2020 117
Chart 63: Gastric Cancer Therapeutics March ket, France, Treatment Usage Patterns (’000s), from 2010 to 2020 118
Chart 64: Gastric Cancer Therapeutics March ket, France, Future March ket Drivers and Restraints, from 2010 to 2020 120
Chart 65: Gastric Cancer Therapeutics March ket, France, Gastric Cancer Drug Sales (USD Million), from 2002 to 2020 121
Chart 66: Gastric Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2002 to 2010 125
Chart 67: Gastric Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2002 to 2010 127
Chart 68: Gastric Cancer Therapeutics March ket, Italy, Patient Volume (’000s), from 2002 to 2010 128
Chart 69: Gastric Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2002 to 2010 129
Chart 70: Gastric Cancer Therapeutics March ket, Italy, March ket Drivers and Restraints, 2009 131
Chart 71: Gastric Cancer Therapeutics March ket, Italy, Historical data al Events Impact on the March ket, 2010 133
Chart 72: Gastric Cancer Therapeutics March ket, Italy, Sales Value (USD Million), from 2010 to 2020 134
Chart 73: Gastric Cancer Therapeutics March ket, Italy, Annual Cost of Therapy ($), from 2010 to 2020 135
Chart 74: Gastric Cancer Therapeutics March ket, Italy, Patient Volume (’000s), from 2010 to 2020 136
Chart 75: Gastric Cancer Therapeutics March ket, Italy, Treatment Usage Patterns (’000s), from 2010 to 2020 137
Chart 76: Gastric Cancer Therapeutics March ket, Italy, Future March ket Drivers and Restraints, from 2010 to 2020 139
Chart 77: Gastric Cancer Therapeutics March ket, Italy, Gastric Cancer Drug Sales (USD Million), from 2002 to 2020 140
Chart 78: Gastric Cancer Therapeutics March ket, Spain, Sales Value (USD Million), from 2002 to 2010 144
Chart 79: Gastric Cancer Therapeutics March ket, Spain, Annual Cost of Therapy ($), from 2002 to 2010 146
Chart 80: Gastric Cancer Therapeutics March ket, Spain, Patient Volume (’000s), from 2002 to 2010 147
Chart 81: Gastric Cancer Therapeutics March ket, Spain, Treatment Usage Patterns (’000s), from 2002 to 2010 148
Chart 82: Gastric Cancer Therapeutics March ket, Spain, March ket Drivers and Restraints, 2009 150
Chart 83: Gastric Cancer Therapeutics March ket, Spain, Historical data al Events Impact on the March ket, 2010 152
Chart 84: Gastric Cancer Therapeutics March ket, Spain, Sales Value (USD Million), from 2010 to 2020 153
Chart 85: Gastric Cancer Therapeutics March ket, Spain, Annual Cost of Therapy ($), from 2010 to 2020 154
Chart 86: Gastric Cancer Therapeutics March ket, Spain, Patient Volume (’000s), from 2010 to 2020 155
Chart 87: Gastric Cancer Therapeutics March ket, Spain, Treatment Usage Patterns (’000s), from 2010 to 2020 156
Chart 88: Gastric Cancer Therapeutics March ket, Spain, Future March ket Drivers and Restraints, from 2010 to 2020 158
Chart 89: Gastric Cancer Therapeutics March ket, Spain, Gastric Cancer Drug Sales (USD Million), from 2002 to 2020 159
Chart 90: Gastric Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2002 to 2010 163
Chart 91: Gastric Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2002 to 2010 164
Chart 92: Gastric Cancer Therapeutics March ket, Japan, Patient Volume (’000s), from 2002 to 2010 165
Chart 93: Gastric Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2002 to 2010 166
Chart 94: Gastric Cancer Therapeutics March ket, Japan, March ket Drivers and Restraints, 2009 168
Chart 95: Gastric Cancer Therapeutics March ket, Japan, Historical data al Events Impact on the March ket, 2010 169
Chart 96: Gastric Cancer Therapeutics March ket, Japan, Sales Value (USD Million), from 2010 to 2020 170
Chart 97: Gastric Cancer Therapeutics March ket, Japan, Annual Cost of Therapy ($), from 2010 to 2020 171
Chart 98: Gastric Cancer Therapeutics March ket, Japan, Patient Volume (’000s), from 2010 to 2020 172
Chart 99: Gastric Cancer Therapeutics March ket, Japan, Treatment Usage Patterns (’000s), from 2010 to 2020 173
Chart 100: Gastric Cancer Therapeutics March ket, Japan, Future Events Expected to Impact the March ket, 2010 175
Chart 101: Gastric Cancer Therapeutics March ket, Japan, Gastric Cancer Drug Sales (USD Million), from 2001 to 2020 176
Chart 102: Gastric Cancer Therapeutics March ket, Brazil, Sales Value (USD Million), from 2002 to 2010 180
Chart 103: Gastric Cancer Therapeutics March ket, Brazil, Annual Cost of Therapy ($), from 2002 to 2010 181
Chart 104: Gastric Cancer Therapeutics March ket, Brazil, Patient Volume (’000s), from 2002 to 2010 182
Chart 105: Gastric Cancer Therapeutics March ket, Brazil, Treatment Usage Patterns (’000s), from 2002 to 2010 183
Chart 106: Gastric Cancer Therapeutics March ket, Brazil, March ket Drivers and Restraints, 2009 185
Chart 107: Gastric Cancer Therapeutics March ket, Brazil, Historical data al Events Impact on the March ket, 2010 186
Chart 108: Gastric Cancer Therapeutics March ket, Brazil, Sales Value (USD Million), from 2010 to 2020 187
Chart 109: Gastric Cancer Therapeutics March ket, Brazil, Annual Cost of Therapy ($), from 2010 to 2020 188
Chart 110: Gastric Cancer Therapeutics March ket, Brazil, Patient Volume (’000s), from 2010 to 2020 189
Chart 111: Gastric Cancer Therapeutics March ket, Brazil, Treatment Usage Patterns (’000s), from 2010 to 2020 191
Chart 112: Gastric Cancer Therapeutics March ket, Brazil, Future Events Expected to Impact the March ket, 2010 193
Chart 113: Gastric Cancer, Russia, Sales Value (USD Million), from 2002 to 2010 194
Chart 114: Gastric Cancer, Russia, Annual Cost of Therapy ($), from 2002 to 2010 195
Chart 115: Gastric Cancer, Russia, Patient Volume (‘000s), from 2002 to 2010 196
Chart 116: Gastric Cancer, Russia, Treatment Usage Patterns, from 2002 to 2010 197
Chart 117: Gastric Cancer Therapeutics March ket, Russia, March ket Drivers and Restraints, 2009 199
Chart 118: Gastric Cancer Therapeutics March ket, Russia, Historical data al Events Impact on the March ket, 2010 200
Chart 119: Gastric Cancer, Russia, Sales Value (USD Million), from 2010 to 2020 201
Chart 120: Gastric Cancer, Russia, Annual Cost of Therapy ($), from 2010 to 2020 202
Chart 121: Gastric Cancer, Russia, Patient Volume (‘000s), from 2010 to 2020 203
Chart 122: Gastric Cancer, Russia, Treatment Usage Patterns, from 2010 to 2020 204
Chart 123: Gastric Cancer Therapeutics March ket, Russia, Future Events Expected to Impact the March ket, 2010 206
Chart 124: Gastric Cancer, India, Sales Value (USD Million), from 2002 to 2010 207
Chart 125: Gastric Cancer, India, Annual Cost of Therapy ($), from 2002 to 2010 208
Chart 126: Gastric Cancer, India, Patient Volume (‘000s), from 2002 to 2010 209
Chart 127: Gastric Cancer, India, Treatment Usage Patterns, from 2002 to 2010 210
Chart 128: Gastric Cancer Therapeutics March ket, India, March ket Drivers and Restraints, 2009 212
Chart 129: Gastric Cancer Therapeutics March ket, India, Historical data al Events Impact on the March ket, 2010 213
Chart 130: Gastric Cancer, India, Sales Value (USD Million), from 2010 to 2020 214
Chart 131: Gastric Cancer, India, Annual Cost of Therapy ($), from 2010 to 2020 215
Chart 132: Gastric Cancer, India, Patient Volume (‘000s), from 2010 to 2020 216
Chart 133: Gastric Cancer, India, Treatment Usage Patterns, from 2010 to 2020 217
Chart 134: Gastric Cancer Therapeutics March ket, India, Future Events Expected to Impact the March ket, 2010 219
Chart 135: Gastric Cancer, China, Sales Value (USD Million), from 2002 to 2010 220
Chart 136: Gastric Cancer, China, Annual Cost of Therapy ($), from 2002 to 2010 221
Chart 137: Gastric Cancer, China, Patient Volume (‘000s), from 2002 to 2010 222
Chart 138: Gastric Cancer, China, Treatment Usage Patterns, from 2002 to 2010 223
Chart 139: Gastric Cancer Therapeutics March ket, China, March ket Drivers and Restraints, 2009 225
Chart 140: Gastric Cancer Therapeutics March ket, China, Historical data al Events Impact on the March ket, 2010 226
Chart 141: Gastric Cancer, China, Sales Value (USD Million), from 2010 to 2020 227
Chart 142: Gastric Cancer, China, Annual Cost of Therapy ($), from 2010 to 2020 228
Chart 143: Gastric Cancer, China, Patient Volume (‘000s), from 2010 to 2020 229
Chart 144: Gastric Cancer, China, Treatment Usage Patterns, from 2010 to 2020 230
Chart 145:Gastric Cancer Therapeutics March ket, China, Future Events Expected to Impact the March ket, 2010 232
Chart 146: Gastric Cancer, Global, Strategic Competitor Assessment of Major March keted Drugs, 2011 236
Chart 147: Gastric Cancer Therapeutics March ket, Global, Sales Forecasted data by Therapies, from 2001 to 2020 238
Chart 148: Gastric Cancer, Global, Herceptin, Sales (USD Million), from 2010 to 2020 241
Chart 149: Gastric Cancer, Globa